BioCryst stock holds firm after a Q2 revenue beat
Published on 08/31/2026 at 21:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
BioCryst Pharmaceuticals, Inc. (BCRX) held at $9.82 on August 28, 2026, after a second-quarter revenue beat and a stronger full-year outlook gave the shares a fresh earnings backdrop. The stock ended that session with a market cap of $2.509 billion, a 52-week range of $6.00 to $11.22, and YTD performance of 25.90%.
Revenue and guidance
In the second quarter, revenue rose 34% year over year to $218.3 million, while earnings came in at $0.35 per share versus an estimate of $0.23. Full-year 2026 revenue guidance moved up to $690 million-$715 million from $635 million-$660 million, and Orladeyo remained guided at $625 million-$645 million.
That combination matters because the quarter showed both speed and concentration: Orladeyo contributed $158.2 million, or about 72% of total revenue, while the company also recognized more than $55 million tied to its European licensing agreement for Navenibart. The mix points to one product still doing most of the work, even as the pipeline adds support.
What the market is pricing
The latest quote snapshot showed intraday trading at $9.82, just above the 200-day moving average of $9.07 and below the 52-week high of $11.22. Volume reached 2,702,946 shares against an average of 4,325,747, and the 1-year target estimate stood at $20.82 in the same market-data view.
RBC Capital also cut its price target to $13 from $14 on August 6, 2026, which keeps the stock in a range where momentum and execution both matter. The gap between the current share price and that target is still wide enough to keep every quarterly update in view.
Orladeyo stays central
Orladeyo remains the main product story because it anchors revenue and frames the company's next step in hereditary angioedema. The company also said its investigational BCX17725 program for Netherton syndrome remains on track for early patient data by the end of 2026.
BioCryst stock at a glance
As of August 28, 2026, BioCryst stock was at $9.82 in Nasdaq trading, with a market cap of $2.509 billion and a 52-week range of $6.00 to $11.22. The next earnings date is November 2, 2026.
Company
Company: BioCryst Pharmaceuticals, Inc.
ISIN: US09058V1035
Ticker: BCRX
Exchange: NasdaqGS
Price (as of August 28, 2026, 4:00 p.m. ET): $9.82 USD
Market cap: $2.509 billion (as of August 28, 2026)
Sector / Industry: Healthcare / Drug Manufacturers - Specialty & Generic
Next earnings date: November 2, 2026
